Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
New Insights into Mesothelioma Immunotherapy
share announcement

New Insights into Mesothelioma Immunotherapy

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".

Deadline for manuscript submissions: closed (28 February 2025) | Viewed by 3591

Special Issue Editor

Dr. Licun Wu

E-Mail Website
Guest Editor
Latner Thoracic Surgery Research Laboratories, Division of Thoracic Surgery, Toronto General Hospital, Princess Margaret Cancer Research Centre, University Health Network, University of Toronto, Toronto, ON M5G 1L7, Canada
Interests: mesothelioma; immunotherapy; immune checkpoint blockade; EMT gene signature

Special Issue Information

Dear Colleagues,

Mesothelioma is a rare cancer associated with exposure to asbestos. Malignant pleural mesothelioma (MPM) is the most common but the prognosis is quite poor. Conventional therapies have very limited efficacy for this disease. Immunotherapy has shown to be promising in preclinical studies and clinical trials; in particular, novel therapy targeting the immune check points has resulted in significant improvement of clinical outcome of the patients with mesothelioma.

The aim of this Special Issue of Biomolecules is to highlight the most recent progress in mesothelioma immunotherapy, which covers mesothelioma, including malignant pleural mesothelioma (MPM) and peritoneal mesothelioma, immunotherapy, immunology, immune profiling, immune response, immunosuppression, immune checkpoint and its inhibitor, immune score, tumor immune microenvironment, and EMT gene signature, etc. We encourage contributions on the topics above as well as molecular biology, genetics, multi-omics, bioinformatics, and meta-analysis computational studies. Basic study and clinical trials addressing this topic are both of particular interest.

Dr. Licun Wu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesothelioma/malignant pleural mesothelioma (MPM)/peritoneal mesothelioma
  • immunotherapy
  • immunology
  • immune profiling
  • immune response
  • immunosuppression
  • immune checkpoint/inhibitor
  • immune score
  • tumor immune microenvironment
  • epithelial-mesenchymal transition (EMT) gene signature

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 401 KiB  
Review
Hyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma
by Susan Luozheng Kong, Zihan Feng, Sangmin Kim, Edra K. Ha, Kero Kamel, Michael Becich, James D. Luketich and Arjun Pennathur
Biomolecules 2025, 15(5), 678; https://doi.org/10.3390/biom15050678 - 7 May 2025
Viewed by 116
Abstract
Pleural mesothelioma (PM) is an aggressive cancer originating from the mesothelial lining of the pleura, with a rising global incidence since the mid-20th century due to asbestos and erionite exposure. PM accounts for 80–90% of all mesothelioma cases and is histologically classified into [...] Read more.
Pleural mesothelioma (PM) is an aggressive cancer originating from the mesothelial lining of the pleura, with a rising global incidence since the mid-20th century due to asbestos and erionite exposure. PM accounts for 80–90% of all mesothelioma cases and is histologically classified into three subtypes—epithelioid, sarcomatoid, and biphasic— with epithelioid carrying the most favorable prognosis. Despite advances in surgery, chemotherapy, radiotherapy, and immunotherapy, PM prognosis remains poor, necessitating more effective, multimodal strategies. Hyperthermic intrathoracic chemoperfusion (HITHOC) has emerged as a promising adjunct to cytoreductive surgery by delivering heated chemotherapy directly to the pleural cavity, potentially improving survival—especially in patients with epithelioid PM. Combining HITHOC with post-surgical immunotherapy represents a novel approach to enhancing both local and systemic anti-tumor responses and targeting microscopic disease and distant metastases. This review explores surgical outcomes after surgery for PM, the therapeutic synergy of HITHOC and immunotherapy, ongoing clinical trials evaluating this multimodal strategy, and its implications for future patient care. Full article
(This article belongs to the Special Issue New Insights into Mesothelioma Immunotherapy)
15 pages, 3038 KiB  
Review
Omics Overview of the SPARC Gene in Mesothelioma
by Licun Wu and Marc de Perrot
Biomolecules 2023, 13(7), 1103; https://doi.org/10.3390/biom13071103 - 11 Jul 2023
Cited by 5 | Viewed by 2888
Abstract
The SPARC gene plays multiple roles in extracellular matrix synthesis and cell shaping, associated with tumor cell migration, invasion, and metastasis. The SPARC gene is also involved in the epithelial-mesenchymal transition (EMT) process, which is a critical phenomenon leading to a more aggressive [...] Read more.
The SPARC gene plays multiple roles in extracellular matrix synthesis and cell shaping, associated with tumor cell migration, invasion, and metastasis. The SPARC gene is also involved in the epithelial-mesenchymal transition (EMT) process, which is a critical phenomenon leading to a more aggressive cancer cell phenotype. SPARC gene overexpression has shown to be associated with poor survival in the mesothelioma (MESO) cohort from the TCGA database, indicating that this gene may be a powerful prognostic factor in MESO. Its overexpression is correlated with the immunosuppressive tumor microenvironment. Here, we summarize the omics advances of the SPARC gene, including the summary of SPARC gene expression associated with prognosis in pancancer and MESO, the immunosuppressive microenvironment, and cancer cell stemness. In addition, SPARC might be targeted by microRNAs. Notably, despite the controversial functions on angiogenesis, SPARC may directly or indirectly contribute to tumor angiogenesis in MESO. In conclusion, SPARC is involved in tumor invasion, metastasis, immunosuppression, cancer cell stemness, and tumor angiogenesis, eventually impacting patient survival. Strategies targeting this gene may provide novel therapeutic approaches to the treatment of MESO. Full article
(This article belongs to the Special Issue New Insights into Mesothelioma Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop